Personalized medicine in traumatic brain injury

Area of Science:

• Neuroscience
• Molecular Biology
• Biomarker Discovery

Background:

• Mild traumatic brain injury (TBI) affects diverse patient populations, leading to varied clinical outcomes.
• While most recover, some develop persistent cognitive, somatic, and neurobehavioral issues.
• The underlying reasons for these varying TBI symptoms remain unclear.

Purpose of the Study:

• To investigate microRNA expression profiles in peripheral blood mononuclear cells (PBMCs) as potential biomarkers for TBI.
• To explore the utility of PBMC microRNAs as an accessible "window" into the brain's molecular changes post-TBI.
• To assess the potential of these biomarkers for understanding TBI progression and chronic traumatic encephalopathy.

Main Methods:

• Analysis of microRNA expression profiles in PBMCs from TBI patients.
• Correlation of microRNA alterations with clinical TBI phenotypes.
• Exploration of PBMC-derived microRNAs as indicators of neurodegenerative processes.

Main Results:

• Evidence suggests microRNA species in PBMCs may mirror molecular alterations relevant to neurodegenerative disorders.
• PBMCs could serve as a clinically accessible source for detecting early molecular changes following TBI.
• Changes in PBMC microRNA expression profiles may reflect TBI-related molecular alterations.

Conclusions:

• PBMC microRNAs show promise as accessible biomarkers for TBI.
• These biomarkers could offer insights into the development and progression of TBI phenotypes, including chronic traumatic encephalopathy.
• Identifying TBI biomarkers may aid in the prevention, prognosis, and treatment of post-concussive disorders.